Skip to content
Inciteful Med

An Introduction to Marfan Syndrome

Last updated:

Marfan syndrome is a genetic connective tissue disorder caused by an FBN1 gene mutation. Modern treatments have improved life expectancy to over 72 years. With early diagnosis and specialized care, most patients can successfully manage heart risks and live full, active lives.

Key Takeaways

  • • Marfan syndrome is a genetic condition affecting connective tissue due to a mutation in the FBN1 gene.
  • • Thanks to modern medicine, life expectancy for people with Marfan syndrome is now over 72 years, comparable to the general population.
  • • The condition can lead to serious internal complications, most notably aortic aneurysms, requiring regular monitoring by a medical team.
  • • Not everyone with the condition has the classic tall and thin appearance; symptoms and severity vary widely among individuals.
  • • About 25 to 30 percent of cases are sporadic, meaning they occur in individuals with no family history of the disorder.

Hearing terms like connective tissue disorder and aortic aneurysm can be incredibly frightening. It is natural to feel overwhelmed or even terrified when you first receive a diagnosis of Marfan syndrome [1][2]. You may be worried about your future, your family, and how your life will change. However, it is important to know that you are living in an era of unprecedented medical progress for this condition.

The Landscape of Life Expectancy

Perhaps the most important thing to understand immediately is how much the outlook for Marfan syndrome has improved. In the 1970s, before modern surgical techniques and medications were available, the average life expectancy for someone with this condition was often cited between 40 and 50 years. Today, because of early diagnosis, better monitoring, and advanced treatments, life expectancy has dramatically increased to more than 72 years—making it comparable to that of the general population [3][4]. With proper care, most people with Marfan syndrome live full, productive lives.

What is Marfan Syndrome?

Marfan syndrome is a genetic condition that affects the body’s connective tissue—the “glue” that provides strength and flexibility to your bones, ligaments, heart valves, and blood vessels [5].

It is caused by a mutation in the FBN1 gene, which tells the body how to make a protein called fibrillin-1 [5]. Fibrillin-1 is a key building block for the fibers that give connective tissue its strength [6]. When this protein is faulty or scarce, two things happen:

  1. The connective tissue becomes weaker than it should be [7].
  2. The body produces too much of a signaling protein called TGF-beta (transforming growth factor-beta) [8][7]. This excess protein can cause tissues to overgrow or change in ways that lead to medical complications, such as an aortic aneurysm (a bulge in the wall of the body’s main artery) [3][9].

For a deeper dive into how this genetic change works, see The Biology and Genetics of Marfan Syndrome. To learn about how doctors evaluate these changes, see How Marfan Syndrome is Diagnosed.

How Common is It?

Marfan syndrome is not as rare as many people think. It is estimated to affect approximately 1 in 5,000 to 1 in 10,000 people worldwide [10][11]. It affects people of all genders and ethnic backgrounds equally [12].

While it is often passed down from a parent (autosomal dominant), about 25% to 30% of cases are sporadic (de novo), meaning the mutation happened for the first time in that individual and was not inherited from a parent [5][13].

Clearing Up Misunderstandings

Because Marfan syndrome is a “spectrum” disorder, it looks different in every person. For more details on what signs to look for, visit Signs and Symptoms of Marfan Syndrome. There are several common myths that can lead to confusion:

  • The “Tall” Myth: While many people with Marfan syndrome are tall and thin with long limbs, this “classic” look is not universal [14]. Some people have the internal features (like heart or eye issues) without the outward appearance [15][16].
  • The “No Sports” Myth: While high-intensity contact sports or heavy weightlifting are usually discouraged to protect the heart, doctors generally recommend staying active with low-impact exercises [3].
  • The “Invisible” Condition: Because the most serious issues—like those affecting the heart—are internal, you may look perfectly healthy to others even while managing a significant medical condition [17][12].

Next Steps and Your Care Journey

Managing Marfan syndrome requires a coordinated approach. You will need to assemble a multidisciplinary team of experts—learn more in Building Your Marfan Care Team. Together, you and your doctors will develop a plan that includes monitoring, daily therapies, and potential interventions outlined in Medications and Life-Saving Surgery and Long-Term Health and Lifestyle.

The Emotional Journey

A diagnosis often brings a complex mix of emotions. Many patients report lower quality of life initially due to the burden of medical appointments and the uncertainty of future health [18][19]. Feelings of anxiety and depression are common and are a normal response to the stress of a chronic condition [1][20]. Validating these feelings is a crucial step in your care. You aren’t just a set of medical symptoms; you are a person navigating a significant life change, and your mental well-being is just as important as your physical health [1][21].

Frequently Asked Questions

What is the life expectancy for someone with Marfan syndrome?
Thanks to modern medical advancements, the average life expectancy for someone with Marfan syndrome is now over 72 years, which is comparable to the general population. Early diagnosis and proper monitoring have dramatically improved outcomes compared to decades past.
What causes Marfan syndrome?
Marfan syndrome is caused by a mutation in the FBN1 gene. This gene tells the body how to make a protein called fibrillin-1, which provides the necessary strength and flexibility to your body's connective tissue.
Do I have to be tall and thin to have Marfan syndrome?
No. While being tall and thin with long limbs is a classic feature of the condition, it is not universal. Many people have internal complications, such as heart or eye issues, without the outward physical appearance.
Can I still exercise if I have Marfan syndrome?
Yes, but you will likely need to make modifications. High-intensity contact sports and heavy weightlifting are generally discouraged to protect your heart. However, doctors usually recommend staying active with safe, low-impact exercises.
Does Marfan syndrome always run in families?
While it is usually passed down from a parent, about 25 to 30 percent of cases are sporadic. This means the gene mutation happened for the first time in that individual and was not inherited from either parent.

Questions for Your Doctor

  • • What is the current measurement or 'Z-score' of my aortic root, and how does it compare to my last scan?
  • • Given my specific FBN1 mutation, are there any particular symptoms or risks I should be more watchful for?
  • • Do you have experience managing Marfan syndrome, or can you refer me to a multidisciplinary center with specialists in genetics, cardiology, and ophthalmology?
  • • What are the 'red flag' symptoms that should prompt me to go to the emergency room immediately?
  • • How will my physical activity levels be monitored, and what types of exercise are safe for me right now?

Questions for You

  • • What were the first symptoms or physical features that led to my diagnosis, and have I noticed any recent changes in my health?
  • • How has this diagnosis affected my mental health, and do I have a support system or counselor to talk to about my fears?
  • • Are there any activities or lifestyle choices I am currently making that I worry might be affecting my heart health?
  • • Have I shared this diagnosis with my biological relatives so they can consider being screened for the condition?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Quality of life in young patients with acute type a aortic dissection in China: comparison with Marfan syndrome and non-Marfan syndrome.

    Lin XF, Xie LF, Zhang ZF, et al.

    BMC cardiovascular disorders 2024; (24(1)):132 doi:10.1186/s12872-024-03740-2.

    PMID: 38424531
  2. 2

    Health Supervision for Children and Adolescents With Marfan Syndrome.

    Tinkle BT, Lacro RV, Burke LW,

    Pediatrics 2023; (151(4)) doi:10.1542/peds.2023-061450.

    PMID: 36938616
  3. 3

    Ulnar Artery Aneurysm as a Late Sequela of Marfan Syndrome.

    Goodenough CJ, Afifi RO, Prakash SK, et al.

    The Journal of hand surgery 2020; (45(11)):1090.e1-1090.e5 doi:10.1016/j.jhsa.2020.01.010.

    PMID: 32213296
  4. 4

    An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome.

    Deleeuw V, De Clercq A, De Backer J, Sips P

    Journal of experimental pharmacology 2021; (13()):755-779 doi:10.2147/JEP.S265271.

    PMID: 34408505
  5. 5

    Clinical Characteristics of Marfan Syndrome in Korea.

    Lim AY, Song JS, Kim EK, et al.

    Korean circulation journal 2016; (46(6)):841-845 doi:10.4070/kcj.2016.46.6.841.

    PMID: 27826344
  6. 6

    The N-Terminal Region of Fibrillin-1 Mediates a Bipartite Interaction with LTBP1.

    Robertson IB, Dias HF, Osuch IH, et al.

    Structure (London, England : 1993) 2017; (25(8)):1208-1221.e5 doi:10.1016/j.str.2017.06.003.

    PMID: 28669633
  7. 7

    Nanoscale Structural Comparison of Fibrillin-1 Microfibrils Isolated from Marfan and Non-Marfan Syndrome Human Aorta.

    Șulea CM, Mártonfalvi Z, Csányi C, et al.

    International journal of molecular sciences 2023; (24(8)) doi:10.3390/ijms24087561.

    PMID: 37108724
  8. 8

    Engineered mutations in fibrillin-1 leading to Marfan syndrome act at the protein, cellular and organismal levels.

    Zeyer KA, Reinhardt DP

    Mutation research. Reviews in mutation research 2015; (765()):7-18.

    PMID: 26281765
  9. 9

    Transforming Growth Factor β Receptor Type I Inhibitor, Galunisertib, Has No Beneficial Effects on Aneurysmal Pathological Changes in Marfan Mice.

    Park JH, Kim MS, Ham S, et al.

    Biomolecules & therapeutics 2020; (28(1)):98-103 doi:10.4062/biomolther.2019.042.

    PMID: 31284709
  10. 10

    Biomarkers of Aortopathy in Marfan Syndrome.

    Iskandar Z, Mordi I, Lang CC, et al.

    Cardiology in review 2020; (28(2)):92-97 doi:10.1097/CRD.0000000000000289.

    PMID: 31985522
  11. 11

    Unprovoked Pulmonary Embolism in a Young Patient with Marfan Syndrome.

    Pak S, Kilgore A, Thornhill R, et al.

    Cureus 2017; (9(9)):e1655 doi:10.7759/cureus.1655.

    PMID: 29142803
  12. 12

    Case Report: FBN1 mutation screening in South African patients with Marfan syndrome.

    Mhlongo F, Feben C, Krause A, Carstens N

    Frontiers in genetics 2025; (16()):1612411 doi:10.3389/fgene.2025.1612411.

    PMID: 40672385
  13. 13

    FBN1 gene mutations in 26 Hungarian patients with suspected Marfan syndrome or related fibrillinopathies.

    Madar L, Szakszon K, Pfliegler G, et al.

    Journal of biotechnology 2019; (301()):105-111 doi:10.1016/j.jbiotec.2019.05.012.

    PMID: 31163209
  14. 14

    A Forme Fruste of Marfan Syndrome: A Case Report.

    Alsheikh N, Hawsawi SA, AlGhamdi A, et al.

    Cureus 2022; (14(11)):e31231 doi:10.7759/cureus.31231.

    PMID: 36505128
  15. 15

    A Case of a Short Stature Patient With Marfan Syndrome: A Tale of Wide Mediastinum.

    Hegazy Y, Abdallah A, Salem A, et al.

    Cureus 2024; (16(12)):e76583 doi:10.7759/cureus.76583.

    PMID: 39881920
  16. 16

    Three-Channeled Aortic Dissection in a Patient without Marfan Syndrome.

    Arita YI, Akutsu K, Yamamoto T, et al.

    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 2018; (24(2)):110-114 doi:10.5761/atcs.cr.17-00066.

    PMID: 29187676
  17. 17

    Differences in Cardiovascular Manifestation of Marfan Syndrome Between Children and Adults.

    Wozniak-Mielczarek L, Sabiniewicz R, Drezek-Nojowicz M, et al.

    Pediatric cardiology 2019; (40(2)):393-403 doi:10.1007/s00246-018-2025-2.

    PMID: 30417312
  18. 18

    Health-related quality of life in adults with Marfan syndrome.

    Stanek Sörner A, Enelund M, Cider Å, Ashman Kröönström L

    Cardiology in the young 2024; (34(12)):2514-2520 doi:10.1017/S1047951124025770.

    PMID: 39354855
  19. 19

    Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome.

    Handisides JC, Hollenbeck-Pringle D, Uzark K, et al.

    The Journal of pediatrics 2019; (204()):250-255.e1 doi:10.1016/j.jpeds.2018.08.061.

    PMID: 30270167
  20. 20

    Prevalence of psychiatric and sleep disorders and their impact on quality of life in children with hypermobile Ehlers-Danlos syndrome: an observational study.

    Hertel AK, Jones JT, Lytch A, et al.

    Rheumatology international 2025; (45(4)):81 doi:10.1007/s00296-025-05836-0.

    PMID: 40131551
  21. 21

    The impact of co-morbidity on the quality of life of people with dementia: findings from the IDEAL study.

    Nelis SM, Wu YT, Matthews FE, et al.

    Age and ageing 2019; (48(3)):361-367 doi:10.1093/ageing/afy155.

    PMID: 30403771

This page provides an introduction to Marfan syndrome for educational purposes only and does not replace professional medical advice. Always consult your geneticist or cardiologist regarding your specific condition and care plan.

Stay up to date

Get notified when new research about Marfan syndrome is published.

No spam. Unsubscribe anytime.